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Patients scheduled for cardiac operation often receive vancomycin before the 
operation to decrease postoperative staphylococcal wound infections. In animal 
studies, vancomycin depressed cardiac function approximately 15%. Because of the 
potentially serious consequences of myocardial depression in patients undergoing 
cardiac operation, we examined the effect of vancomycin infusion on cardiac 
hemodynamics in patients scheduled for cardiac operation. Patients who were 
scheduled for cardiac operation and vancomycin prophylaxis were enrolled in our 
study. After baseline cardiac output, mean arterial pressure, central venous 
pressure, and pulmonary eapillary wedge pressure were measured, 1 gm of 
vancomyein HCI was infused over 1 hour. Cardiac output, mean arteriai pressure, 
central venous pressure, and pulmonary capillary wedge pressure were measured at 
15, 30, 60, 90, and 120 minutes after the start of the infusion. In the 46 patients that 
completed the study, no significant change was observed in cardiac output or 
systemic vascular resistance at any time when compared with baseline. Mean 
arterial pressure increased signifieantly (p = 0.03) between baseline (90.8 - 2.4 
standard error of mean) and 90 minutes (94.1 - 2.4 standard error of mean). One 
patient had a transient 30% fall in mean arterial pressure and systemic vascular 
resistance with facial flushing during the infusion. In conclusion, we found that 
vancomycin fusion over 1 hour in patients before cardiac operation is safe and not 
associated with cardiac depression. (J THORAC CARDIOVASC SURG 1995;109:561-4) 
J. M. Rosenberg, MD, J. A. Wahr, MD, and K. A. Smith, RN, BSN, Ann Arbor, Mich. 
V ancomycin is used in the preoperative period to decrease postoperative staphylococcal wound in- 
fections 1, 2 However, vancomycin depressed cardiac 
function approximately 15% in clinically relevant 
doses in open chest dogs and in Langendorff cat 
heart preparations. 3 Peak effects were noted 1 hour 
after administration. When patients received vanco- 
mycin, 1 gm was infused over 30 minutes before 
cardiac operation; hypotension occurred in 25% of 
patients (>20% decrease in mean arterial pressure 
[MAP]) and was severe (>50% decrease) in 8% of 
patients compared with baseline. 4 Because of the 
potentially serious consequences of cardiac depres- 
sion in patients undergoing cardiac operation, we 
examined the effect of vancomycin on cardiac he- 
modynamics in patients cheduled for cardiac oper- 
ation. 
Methods 
After obtaining approval from the institutional review 
board and informed consent, patients re¢eiving vancomy- 
cin before cardiac operation were enrolled in our study. 
After baseline cardiac output (CO), MAP, central venous 
pressure (CVP), and pulmonary capillary wedge pressure 
(PCWP) were measured, 1 gm of vancomycin HC1 (Lilly 
Research Läboratories, Indianapolis, Ind.) diluted in 50 cc 
of 5% dextrose in water, was administered over 1 hour by 
means of an infusion pump (Baxter Healthcare Corp., 
Santa Ana, Calif.). The vancomycin infusion and all 
experimental measurements were completed uring the 
patients' 2-hour resting period in the preoperative holding 
room, during which no other medications were infused. 
Hemodynamic measurements were repeated at 15, 30, 60, 
90, and 120 minutes after the start of the infusion. Cardiac 
outputs were the average of three end expiration mea- 
surements and measured with a 7.5F Swan-Ganz ther- 
modilution catheter (Baxter Healthcare) connected to an 
ùAbbott cardiac output computer (Abbott Laboratories, 
N. Chicago, Ill.). Typical preoperative s dation was ad- 
ministered and included midazolam or lorazepam and 
fentanyl which was given at least 30 minutes before the 
experiment. The patients also received their usual cardiac 
medications. No antihistamines or steroids were given. 
Data were analyzed by analysis of variance for repeated 
measures with the Scheffé F test. Individual ditterences 
were analyzed with unpaired t tests. Reliability measures 
were determined with the methods of Vonesh and 
Schork. 5
Results 
Of the 52 patients enrolled in the study, eight 
patients were removed because they underwent 
operation before data ¢ollection was complete. Of 
the 46 patients who completed the study, 34 under- 
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Fig. 1. Cardiac output (CO)during vancomycin fusion 
(0 to 60 minutes) and 60 minutes after. Values are means 
_+ SEM; no differences had a level of significance -<0.05. 
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Fig. 2. MAP during vancomycin i fusion (0 to 60 min- 
utes) and 60 minutes after. Values are means + SEM. 
*Level of significance for difference from other values 
-<0.05. 
weht coronary artery bypass grafting, eight had 
aortic valve replacement, and four had mitral valve 
replaeement. No significant (so < 0.05) difference at 
baseline was found between the patients undergoing 
valve operations compared with those undergoing 
coronary artery bypass grafting in CO, MAP, or 
SVR. 
Vancomycin infusion had no effect on CO, as 
shown in Fig. 1. This result did not change when the 
patients undergoing coronary artery bypass grafting 
or valve operations were compared separately. The 
changes een in MAP are shown in Fig. 2 (p = 0.03). 
A small increase in MAP between baseline (90.8 + 
2.24 standard error of mean [SEM]) and 90 minutes 
(94.1 + 2.4 SEM) was found with the use of t tests. 
Vancomycin infusion had no effect on SVR, as 
shown in Fig. 3. One patient had a transient 30% fall 
dynes sec cm-5 +/-SEM 
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Fig. 3. SVR during vancomycin infusion (0 to 60 min- 
utes) and 60 minutes after. Values are means _+ SEM; no 
differences had a level of significance -<0.05, 
in MAP and SVR with facial ftushing during the 
infusion. 
The probability that a 15% decrease in cardiac 
output is related to vancomycin infusion that was 
not detected by this study is less than 1 in 1000 
(power ->0.999). 
Discussion 
Our results show that 1 gm of vancomycin can be 
safely infused over 1 hour and that it is not associ- 
ated with a decrease in CO in patients with known 
cardiac disease. These results are contrary to wide- 
spread concerns 6-s about vancomycin-induced car- 
diac depression in patients with poor cardiac func- 
tion according to the 1972 animal studies of Cohen 
and associates. 3 Decreased CO has not been asso- 
ciated with vancomycin infusion in human beings 
except in case reports of rapid infusions with lethal 
outcomes.9,10 
• The cardiac effects of vancomycin in human be- 
ings have been examined by two groups of investi- 
gators. Romanelli and associates al administered 1 
gm of vancomycin over 30 minutes to 30 patients on 
arrival to the operating room, after induction, and 
every 12 hours after the operation and compared 
hemodynamic measurements with those of 28 pa- 
tients receiving normal saline solution. Measure- 
ments were taken before induction, after induction, 
during the operation, and every 4 hours for 24 hours 
after the operation. They found no difference be- 
tween the groups before and after induction. In- 
creased CO and heart rate with a decreased SVR 
and MAP were found after the operation in the 
vancomycin group, which necessitated vasopressor 
administration. These results were consistent with 
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Table I. Hemodynamic changes during vancomycin i fusion (values + SEM) 
Baseline 15 min 30 min 60 min 90 min 120 min 
CO 5.2 _+ 0.17 5.28 +_ 0.21 5.28 ± 0.18 5.44 ± 0.2 5.24 + 0.2 5.27 + 0.29 
MAP 90.8 + 2.2 90.4 + 2.5 91 -+ 2.7 89.8 ± 2.4 94 + 2.4* 93.5 ± 2.4 
SVR 1386 ± 54 1386 + 59 1382 + 54 1338 +- 57 1445 ± 59 1338 _+ 54 
*p -< 0.05. 
vasodilation. Their experiment, although it shows 
vasodilatory properties of vancomycin, does not 
adequately examine whether vaneomycin is a car- 
diac depressant. Specifically, vancomycin was not 
administered by infusion pump, the time period of 
predicted greatest effect coincided with induction of 
anesthesia, and the number of subjects was not 
sufficient to detect a 20% difference in cardiac 
output as predicted by the data of Cohen and 
associates. 3 Furthermore, the vasodilatory effects 
were noted only after several doses of vancomycin, 
which makes it unclear whether it was a vancomycin 
effect. 
Stier and associates 12examined the hemodynamic 
effects of 1 gm of vancomycin infused over 30 
minutes given to 16 patients after their cardiac 
operation. No significant hemodynamic hanges 
were found, and one patient had symptoms consis- 
tent with "red-man syndrome," but the number of 
patients was not sutficient to detect a 20% decrease 
in CO. Most (13 of 16) of the patients had already 
received vancomycin in the intraoperative period 
before experimental measurements. 
The prevalence of hypotension i patients receiv- 
ing vancomycin before cardiac operation was exam- 
ined in the recent study by Valero, Gomar, and 
Fita. « They found a 25% prevalence of hypoten- 
sion when vancomycin was infused over 30 minutes 
after induction of anesthesia. CO was not reported. 
Other studies in patients without cardiac operation 
included less hypotension. 13' 14 We did not experi- 
ence a similar reduction in MAP when the vanco- 
mycin was administered before the operation over a 
longer period (60 minutes), except in one patient 
who had a 30% decrease in MAP and SVR with 
no change in CO. Although not addressed irectly 
by this investigation, the difference in rates of hypo- 
tension can be explained as a disparity in the 
magnitude of the anaphylactoid response to vanco- 
mycin (altered SVR) and not a direct myocardial 
depression. 
The prevalence of anaphylactoid reaction to van- 
comycin infusion is 0% to 90%, depending on dose, 
infusion time, definition of reaction, and eoncomi- 
tant medications. Experimental studies how a dose- 
related increase in histamine release and that the 
severity of the symptoms i directly related to hista- 
mine level. Hypotension does not develop during 
rapid infusion of vancomyein when dogs are given 
H1 blockers. It is reasonable to conclude that hypo- 
tension is a severe response to histamine release in 
a spectrum of responses ranging from flushing to 
cardiovascular collapse. 14 
Differences in speed of administration alter peak 
serum levels. One gram of vancomycin i fused over 
60 minutes produced mean plasma concentrations 
of 63 mg/L at the completion of the infusion and 23 
mg/L 2 hours after the infusion (Lilly Research 
Laboratories, unpublished ata, 1984). Infusion of 
500 mg over 30 minutes produces mean serum levels 
of 49 mg/L. Infusion of 1 gram over the same 30 
minute interval would likely yield serum levels near 
100 mg/L. Increased serum vaneomycin and thus 
increased serum histamine is probably responsible 
for the 25% prevalence of hypotension seen by 
Valero, Gomar, and Fita. 4 Whether anesthetic 
agents contributed to the hypotension is not known. 
The maximal infusion rate suggested by the manu- 
facturer is 600 mg/hr. 
We found no evidence that vancomycin infusion 
over 1 hour in patients before cardiac operation is 
associated with any decrease in CO or SVR, con- 
trasting with the animal studies of Cohen and asso- 
ciates. 3 As given in this study, anticipated plasma 
vancomycin levels are similar to the expected values 
in their dog/cat preparations at the time of peak 
myoeardial depression. Perhaps the different out- 
comes in the whole animal preparations are related 
to different histamine levels, impurities in earlier 
preparations, 15 or late manifestations of bolus injec- 
tion, but these potential factors cannot explain why 
vancomycin caused myocardial depression in their 
isolated heart experiments. 
In conclusion, vancomycin i fusion of I gm over 1 
hour is safe and free of myocardial depression in 
patients before cardiac operation. The cardiac de- 
pression seen in animal studies was not observed in 
human beings. 
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